The next generation biopharmaceuticals

Affibody appoints Dr. Fredrik Frejd as VP Research

2011-09-19

Dr. Frejd has over fifteen years of experience in life science research with particular expertise in tumor biology, phage display and therapeutic protein engineering of antibody fragments and alternative scaffolds. In his position as Vice Preseident Research, Dr. Frejd will be closely involved in the development and management of Affibody’s therapeutic programmes. He will report to David Bejker, CEO.

Dr. Frejd joined Affibody AB as project manager in 2002 and has since been instrumental in developing the therapeutics program within the company. In 2010 he was appointed Director Discovery at the company, overseeing the internal research portfolio. Dr Frejd is affiliated with the unit for Biomedical radiation sciences, Uppsala University, as associate professor.

Dr. Frejd received his Ph.D. in Molecular Biology from the Institute of Pharmaceutical Sciences, ETH Zurich, Switzerland, working on therapeutic targeting of tumoral angiogenesis.

Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.

Affibody is developing a portfolio of innovative drug projects and, in addition, offers the half-life extension technology, Albumod™, for outlicensing.

Affibody has ongoing commercial relationships with several companies including Algeta, Amylin, Swedish Orphan Biovitrum, GE, and Thermo Fisher.

Affibody was founded in 1998 by researchers from the Royal Institute of Technology and the Karolinska Institute and is based in Stockholm, Sweden. Major shareholders in the Company include HealthCap and Investor Growth Capital.

Further information can be found at: www.affibody.com

Affibody in short

Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.

Upcoming reports Financial calendar

  • Interim Report Q2 (August 23, 2018)